Dataset Information

Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.

ABSTRACT: To investigate provider utilization of pharmacist support in the delivery of pharmacogenetic testing in a primary care setting.Two primary care clinics within Duke University Health System participated in the study between December 2012 and July 2013. One clinic was provided with an in-house pharmacist and the second clinic had an on-call pharmacist.Providers in the in-house pharmacist arm consulted with the pharmacist for 13 of 15 cases, or about one of every four patients tested compared with one of every 7.5 patients in the on-call pharmacist arm. A total of 63 tests were ordered, 48 by providers in the pharmacist-in-house arm.These findings suggest that the availability of an in-house pharmacist increases the likelihood of pharmacogenetic test utilization.

SUBMITTER: Haga SB

PROVIDER: S-EPMC5558524 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.

Haga Susanne B SB Mills Rachel R Moaddeb Jivan J Allen LaPointe Nancy N Cho Alex A Ginsburg Geoffrey S GS

Pharmacogenomics 20170222 4

<h4>Aim</h4>To investigate provider utilization of pharmacist support in the delivery of pharmacogenetic testing in a primary care setting.<h4>Methods</h4>Two primary care clinics within Duke University Health System participated in the study between December 2012 and July 2013. One clinic was provided with an in-house pharmacist and the second clinic had an on-call pharmacist.<h4>Results</h4>Providers in the in-house pharmacist arm consulted with the pharmacist for 13 of 15 cases, or about one ...[more]

PMID: 28244812

Similar Datasets

Project description:INTRODUCTION:Intensive behavioral counseling is effective in preventing type 2 diabetes, and insurance coverage for such interventions is increasing. Although primary care provider referrals are not required for entry to the Centers for Disease Control and Prevention (CDC)-recognized National Diabetes Prevention Program lifestyle change program, referral rates remain suboptimal. This study aims to assess the association between primary care provider behaviors regarding prediabetes screening, testing, and referral and awareness of the CDC-recognized lifestyle change program and the Prevent Diabetes STAT: Screen, Test, and Act Today™ toolkit. Awareness of the lifestyle change program and the STAT toolkit, use of electronic health records, and the ratio of lifestyle change program classes to primary care physicians were hypothesized to be positively associated with primary care provider prediabetes screening, testing, and referral behaviors. METHODS:Responses from primary care providers (n=1,256) who completed the 2016 DocStyles cross-sectional web-based survey were analyzed in 2017 to measure self-reported prediabetes screening, testing, and referral behaviors. Multivariate logistic regression was used to estimate the effects of primary care provider awareness and practice characteristics on these behaviors, controlling for provider characteristics. RESULTS:Overall, 38% of primary care providers were aware of the CDC-recognized lifestyle change program, and 19% were aware of the STAT toolkit; 27% screened patients for prediabetes using a risk test; 97% ordered recommended blood tests; and 23% made referrals. Awareness of the lifestyle change program and the STAT toolkit was positively associated with screening and referring patients. Primary care providers who used electronic health records were more likely to screen, test, and refer. Referring was more likely in areas with more lifestyle change program classes. CONCLUSIONS:This study highlights the importance of increasing primary care provider awareness of and referrals to the CDC-recognized lifestyle change program.

Dataset Information

Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.

Publications

Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets